Esperion Therapeutics Inc (ESPR)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form PREM14A - Preliminary proxy statements relating to merger or acquisition

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years – – A Secondary Analysis of...

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12...

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Esperion to be Acquired by ARCHIMED

Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to...

Esperion to Report First Quarter 2026 Financial Results on May 7

ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements